- Molecular NameTamsulosin
- Synonymtamsulosin; YM-617
- Weight408.519
- Drugbank_IDDB00706
- ACS_NO106133-20-4
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.62
- pkapKa8.4 (secondary amine), 10.2 (sulfonamide)
- LogD (pH=7, predicted)-0.62
- Solubility (experiment)Sparingly soluble in water
- LogS (predicted, ACD/Labs)(ph=7)-1.87
- LogSw (predicted, AB/LogsW2.0)0.23
- Sw (mg/ml) (predicted, ACD/Labs)0.15
- No.of HBond Donors3
- No.of HBond Acceptors7
- No.of Rotatable Bonds11
- TPSA108.26
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn α1a-selective alpha blocker used in the symptomatic treatment of benign prostatic hyperplasia (BPH).
- Absorption_value100.0
- Absorption (description)Absorption of tamsulosin HCI from capsules 0.4 mg is essentially complete (>90%) following oral administration under fasting conditions.
- Caco_2N/A
- BioavailabilityN/A
- Protein binding99.0
- Volume of distribution (VD)0.20 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized primarily by CYP3A and CYP2D6.
- Half life6.8 h (Apparent t1/2 after oral dose in patients is 14 to 15 hours, reflecting controlled release from modified-release granules)
- Excretion76% renal
- Urinary Excretion12.7
- Clerance0.62 ml/min/kg
- ToxicityN/A
- LD50 (rat)LD50=650 mg/kg
- LD50 (mouse)N/A